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Abstract
Masseter muscle hypertrophy is a rare condition of unknown cause which is important in the differential diagnosis 
of head and neck masses, located in the cheek. Several treatment options reported for masseter hypertrophy, which 
range from simple pharmacotherapy to more invasive surgical reduction. Botulinum toxin type A is a powerful 
neurotoxin which is produced by the anaerobic organism Clostridium botulinum and when injected into a muscle 
causes interference with the neurotransmitter mechanism producing selective paralysis and subsequent atrophy of 
the muscle. Injection of botulinum toxin type A into the masseter muscle is generally considered a less invasive 
modality and has been advocated for cosmetic sculpting of the lower face. Botulinum toxin type A injection is 
considered to be a beneficial treatment modality in masseter muscle hypertrophy patients. The aim of this article is 
to report two cases of masseteric muscle hypertrophy which were treated with  botulinum toxin type A injection. 
Marked changes in facial feature were achieved 3 months after the procedure.
Key words: Masseter muscle, hypertrophy, botulinum toxin type A.
Baş B, Özan B, Muğlali M, Çelebi N. Treatment  of   masseteric hypertro-
phy with  botulinum toxin: A report of two cases. Med Oral Patol Oral Cir 
Bucal. 2010 Jul 1;15 (4):e649-52.  
 http://www.medicinaoral.com/medoralfree01/v15i4/medoralv15i4p649.pdf
Article Number: 3078           http://www.medicinaoral.com/
© Medicina Oral S. L. C.I.F. B 96689336 - pISSN 1698-4447 - eISSN: 1698-6946
eMail:  medicina@medicinaoral.com 
Indexed in: 
-SCI EXPANDED
-JOURNAL CITATION REPORTS
-Index Medicus / MEDLINE  /  PubMed                       
-EMBASE, Excerpta Medica
-SCOPUS
-Indice Médico Español                                                        
Introduction
Masseteric  hypertrophy  (MH)  is  recognized  as  an 
asymptomatic  enlargement  of  one  or  both  masseter 
muscles (1). Although it is tempting to point to maloc-
clusion, bruxism, clenching, or temporomandibular joint 
disorders, the etiology in the majority of cases is unclear 
(2). A congenital variety also exists, but acquired MH is 
by far most  frequent (1).  Most  cases of  MH  are  bilat-
eral  and  symmetric,  but asymmetry  is not  unusual. 
Unilateral  occurrence  also can  be  seen  when  patients 
chew  or  clench  primarily on  one  side (1).
The traditional method of treatment for MH is the sur-
gical partial excision of masseter muscle under general 
anesthesia. Complications from surgical excision of 
masseter include hematoma formation, facial nerve pa-
ralysis, infection, mouth opening limitation and seque-
lae from general anesthesia (3). Injection of botulinum 
toxin type A into the masseter muscle is first introduced 
by Smyth, and Moore and Wood in 1994 and considered 
a less invasive modality and for cosmetic sculpting of 
the lower face (4,5). Botulinum toxin type A injection is 
reported to be a safe and effective treatment modality in 
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orofacial dystonies, sialorrhea, frey’s syndrome, muscle 
hypertrophies, etc (6-9). 
Botulinum toxin type A is a powerful neurotoxin which 
is produced by the anaerobic organism Clostridium botu-
linum and when injected into a muscle causes interference 
with the neurotransmitter mechanism producing selective 
paralysis and subsequent atrophy of the muscle (10,11).
The aim of this report is to present two cases of mas-
seter muscle hipertrophy which were treated with botu-
linum toxin type A injection.  
Case Reports
Case report 1 
A 26 year-old woman with a swelling on her left masse-
teric region which existed for 2 years was refered to our 
clinic. The patient had no history of systemic diseases. 
Extraoral examination  showed  an  obvious  unilateral 
swelling  centered  over  the  mandibular  angle  (Fig. 
1a). Palpation  indicated  that  the  swelling  tissue  was 
normal  in tone  and  non-tender.  When the patient was 
asked to clench, the swelling became more prominent 
and firm. Intraoral examination revealed a missing 
maxillary molar tooth at right side. The patient revealed 
that she uses the left side while chewing. Magnetic reso-
nance imaging (MRI) showed no underlying pathology. 
Botulinum toxin A injection into the masseter muscle 
was planned for the patient. 
Case report 2
A 28 year-old man with bilateral swelling of masseteric 
regions was refered to our clinic (Fig. 2a).  He was in 
Fig. 1a. Extraoral view of the first patient before injection b : extraoral view of the patient, 3 months after injection. 
Fig. 2a. Extraoral view of the second patient before injection b : Extraoral view of the second patient, 3 months 
after injection. 
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good health. Extraoral examination revealed bilateral 
hypertrophic masseter muscles. No abnormality was 
seen in intraoral examination and there was no poten-
tial etiologic factor in his history. MRI and Ultrasono-
graphic imaging showed no underlying pathology.
Injection Procedure
Before the procedure the nature and the established use 
of botulinum toxin A as well as its potential side effects 
were explained and signed inform consent was obtained 
from each patient. Botulinum toxin A (BOTOX®) was 
supplied a freeze-dried powder of 100 units and was re-
constituted with 2 ml of sterile saline solution, giving a 
concentration of 50 units ml-1. In the first case, percu-
taneus intramuscular injection of the botulinum toxin A 
was performed to the hypertrophic muscle using 2 ml 
syringe with 25 G needle. 75 units botulinum toxin A 
was injected equally into three points at the center of the 
lower third of the masseter muscle which were located 
1 cm from each other (Fig. 3). In the second case, per-
cutaneus intramuscular injection of the botulinum toxin 
A was performed to the hypertrophic muscle bilaterally 
using 2 ml syringe with 25 G needle. 50 units botuli-
num toxin A was injected each side, equally into three 
points at the center of the lower third of the masseter 
muscle which were located 1 cm from each other. 
Facial paralysis was seen in case 1 that improved in 2 
weeks. There was no postoperative complication in case 
2. The  patients  were  seen  for follow-up  examination, 
and  within  3  months  satisfactory masseter muscle 
atrophy  occurred in both patients  (Fig. 1b,2b). Both pa-
tients are pleased with their present facial appearance.
Fig. 3. Intramuscular injection of the botulinum toxin type A.
Discussion
The etiology of masseter muscle hypertrophy has been 
attributed to a number of factors such as emotional 
stress, chronic bruxism, masseteric hyper-function and 
para-function, and microtrauma (12-15). In our first 
case the etiologic factor was probably unilateral che-
wing habit of the patient due to her missing teeth. After 
the injection, prosthetic reconstruction was performed 
to cease the etiology and stabilize the outcome in this 
case. However, there was no history of any etiological 
factors in the second case. 
Diagnosis of masseter hypertrophy cannot solely be 
based on clinical findings and there are conﬂicting re-
commendations in the literature for investigating pa-
tients presenting with benign bilateral masseter hyper-
trophy. It is important to make differential diagnosis of 
head and neck masses, particularly a unilateral mass 
located in the cheek (16). The possible underlying patho-
logical factors should be assessed carefully with imaging 
techniques before the treatment. 
The possible complications of this procedure are exter-
nal scar and damage to the mandibular branch of the 
facial nerve, change in bite force, speech disturbance, 
muscle pain, facial asymmetry, and prominent zygoma 
(17,18). In our first case temporary marginal  mandibu-
lar  nerve  paralysis was occurred and improved in two 
weeks. Special attention   should be focused on the risk 
of damaging the facial nerve during the injection. Ho-
wever, this can be an inevitable complication due to 
anatomic variations.
Perhaps the biggest limitation of botulinum toxin the-
rapy is that the treatment effect wears away in 6 months 
and the original condition returns. Unlike surgical ex-
cision of muscle tissue that reduces the actual number 
of muscle cells, botulinum toxin type A only reduces 
muscle volume temporarily (3). Therefore, patients have 
to be informed about the recurrence rate after the pro-
cedure. 
In this report, we presented the use of botulinum toxin 
A injection in the treatment of two patients with masse-
ter hypertrophy. Satisfactory esthetic improvement was 
maintained in both cases. However, well-designed, ade-
quately powered, randomised controlled clinical trials 
are  needed for making a definate comment on the suc-
cess of the  this treatment.  
References
1. Mandel L, Tharakan M. Treatment of unilateral masseteric hyper-
trophy with botulinum toxin: case report. J Oral Maxillofac Surg. 
1999;57:1017-9.
2. Addante RR. Masseter muscle hypertrophy: report of case and 
literature review. J Oral Maxillofac Surg. 1994;52:1199-202. 
3. Ham JW. Masseter muscle reduction procedure with radiofrequen-
cy coagulation. J Oral Maxillofac Surg. 2009;67:457-63. 
4. Smyth AG. Botulinum toxin treatment of bilateral masseteric 
hypertrophy. Br J Oral Maxillofac Surg. 1994;32:29-33. 
5. Moore AP, Wood GD. The medical management of masseteric 
Med Oral Patol Oral Cir Bucal. 2010 Jul 1;15 (4):e649-52.                                                                                                                        Masseter muscle hypertrophy treated with botulinum toxin
e652
hypertrophy with botulinum toxin type A. Br J Oral Maxillofac 
Surg. 1994;32:26-8. 
6. Maestre-Ferrín L, Burguera JA, Peñarrocha-Diago M, Peñarro-
cha-Diago M. Oromandibular dystonia: a dental approach. Med Oral 
Patol Oral Cir Bucal. 2009;15:e25-7. 
7. Martos Díaz P, Bances del Castillo R, Mancha de la Plata M, Naval 
Gías L, Martínez Nieto C, Lee GY, et al. Clinical results in the man-
agement of Frey’s syndrome with injections of Botulinum toxin. Med 
Oral Patol Oral Cir Bucal. 2008;13:E248-52. 
8. Fuster Torres MA, Berini Aytés L, Gay Escoda C. Salivary gland 
application of botulinum toxin for the treatment of sialorrhea. Med 
Oral Patol Oral Cir Bucal. 2007;12:E511-7. 
9. Luna Ortiz K, Rascon Ortiz M, Sansón Riofrio JA, Villavicencio 
Valencia V, Mosqueda Taylor A. Control of Frey’s syndrome in pa-
tients treated with botulinum toxin type A. Med Oral Patol Oral Cir 
Bucal. 2007;12:E79-84. 
10. Kwon JS, Kim ST, Jeon YM, Choi JH. Effect of botulinum toxin 
type A injection into human masseter muscle on stimulated parotid 
saliva ﬂow rate. Int J Oral Maxillofac Surg. 2009;38:316-20. 
11. Al-Muharraqi MA, Fedorowicz Z, Al Bareeq J, Al Bareeq R, 
Nasser M. Botulinum toxin for masseter hypertrophy. Cochrane Da-
tabase Syst Rev. 2009;1:CD007510. 
12. Von Lindern JJ, Niederhagen B, Appel T, Bergé S, Reich RH. 
Type A botulinum toxin for the treatment of hypertrophy of the mas-
seter and temporal muscles: an alternative treatment. Plast Reconstr 
Surg. 2001;107:327-32. 
13. Harriman DG. The histochemistry of reactive masticatory mus-
cle hypertrophy. Muscle Nerve. 1996;19:1447-56. 
14. Serrat A, García-Cantera JM, Redondo LM. Isolated unilateral 
temporalis muscle hypertrophy. A case report. Int J Oral Maxillofac 
Surg. 1998;27:92-3. 
15. Wilson PS, Brown AM. Unilateral temporalis muscle hypertro-
phy: case report. Int J Oral Maxillofac Surg. 1990;19:287-8. 
16. Riefkohl R, Georgiade GS, Georgiade NG. Masseter muscle 
hypertrophy. Ann Plast Surg. 1984;12:528-32. 
17. To EW, Ahuja AT, Ho WS, King WW, Wong WK, Pang PC, et al. 
A prospective study of the effect of botulinum toxin A on masseteric 
muscle hypertrophy with ultrasonographic and electromyographic 
measurement. Br J Plast Surg. 2001;54:197-200. 
18. Ahn KY, Kim ST. The change of maximum bite force after bot-
ulinum toxin type a injection for treating masseteric hypertrophy. 
Plast Reconstr Surg. 2007;120:1662-6. 
